RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire/ -- RosVivo Therapeutics, Inc. (hereinafter referred to as "RosVivo") announced that it has signed a Material Transfer Agreement (MTA) with one of the largest global pharmaceutical companies Eli Lilly and Company (hereinafter referred to as "Eli Lilly...
Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.
SEOUL, South Korea, May 30, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced onMay 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc. ("Rosvivo"), an American new drug developer, for about5.5 million U.S. dollars. As a result, Nexturn...
Nexturn Bio Inc. decided to invest in the development of a new drug pipeline for diabetes treatment using miRNA
SEOUL, South Korea, May 7, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug developer, as its first investment destination. RosVivo recently developed RSVI-301, a new d...
The world's first-in-class miRNA therapeutics to cure diabetes by pancreatic beta cell regeneration
SEOUL, South Korea, May 7, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), has selected its first technological investment target to expand its new bio business. Nexturn Bio announced that it has secured a 50% stake in RosVivo Therapeutics, Inc....
